R&G PharmaStudies Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022
Revenue	851.01	744	721.37	637.52	608.43
Revenue Growth (YoY)	14.38%	3.14%	13.15%	4.78%	25.59%
Cost of Revenue	555.36	468.08	434.34	402.62	375.25
Gross Profit	295.64	275.92	287.04	234.9	233.17
Selling, General & Admin	102	91.29	94.45	75.34	71.85
Research & Development	61.97	56.83	52.86	49.99	41.19
Other Operating Expenses	3.98	3.39	3.76	3.01	3.43
Operating Expenses	173.13	154.88	155.93	131.92	124.02
Operating Income	122.51	121.05	131.11	102.98	109.15
Interest Expense	-2.86	-3.44	-0.6	-0.67	-0.58
Interest & Investment Income	21.25	23.17	34.6	15.04	5.46
Currency Exchange Gain (Loss)	-3.47	1.72	1.38	5.73	-1.34
Other Non Operating Income (Expenses)	-0.38	-1.79	-0.35	-0.58	-0.41
EBT Excluding Unusual Items	137.05	140.7	166.14	122.5	112.28
Gain (Loss) on Sale of Investments	10.95	11.28	3.98	0.91	-2.1
Gain (Loss) on Sale of Assets	-0.01	-0.07	-0.02	-0.02	-0.02
Other Unusual Items	7.16	5.87	12.37	5.5	3.44
Pretax Income	155.15	157.79	182.47	128.89	113.6
Income Tax Expense	16.85	16	19.61	14.75	13.24
Earnings From Continuing Operations	138.29	141.79	162.86	114.13	100.35
Minority Interest in Earnings	-1.39	-1.57	-0.33	-0.69	-1.12
Net Income	136.9	140.22	162.53	113.45	99.24
Net Income to Common	136.9	140.22	162.53	113.45	99.24
Net Income Growth	-2.37%	-13.73%	43.27%	14.32%	18.37%
Shares Outstanding (Basic)	96	95	96	82	72
Shares Outstanding (Diluted)	96	95	96	82	72
Shares Change (YoY)	0.36%	-0.64%	16.78%	14.43%	-0.38%
EPS (Basic)	1.43	1.47	1.69	1.38	1.38
EPS (Diluted)	1.43	1.47	1.69	1.38	1.38
EPS Growth	-2.72%	-13.17%	22.68%	-0.09%	18.82%
Free Cash Flow	94.93	134.78	172.68	109.64	76.29
Free Cash Flow Per Share	0.99	1.41	1.80	1.33	1.06
Dividend Per Share	0.160	0.160	0.200	0.156	-
Dividend Growth	-	-20.00%	27.96%	-	-
Gross Margin	34.74%	37.09%	39.79%	36.85%	38.32%
Operating Margin	14.40%	16.27%	18.18%	16.15%	17.94%
Profit Margin	16.09%	18.85%	22.53%	17.79%	16.31%
Free Cash Flow Margin	11.15%	18.12%	23.94%	17.20%	12.54%
EBITDA	129.32	144.37	153.73	110.43	135.31
EBITDA Margin	15.20%	19.40%	21.31%	17.32%	22.24%
D&A For EBITDA	6.81	23.32	22.62	7.44	26.16
EBIT	122.51	121.05	131.11	102.98	109.15
EBIT Margin	14.40%	16.27%	18.18%	16.15%	17.94%
Effective Tax Rate	10.86%	10.14%	10.75%	11.45%	11.66%
Revenue as Reported	851.01	744	721.37	637.52	608.43
Advertising Expenses	-	-	-	-	1.61

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.